266
Views
11
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study

, , , ORCID Icon, , ORCID Icon & show all
Pages 289-297 | Received 25 Aug 2020, Accepted 31 Dec 2020, Published online: 20 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Gitte Dam, Henning Grønbæk, Anna Sundlöv, Johan Botling, Anders Sundin, Rene Horsleben Petersen, Staffan Welin, Espen-Thiis Evensen, Halfdan Sorbye, Elizaveta Tabaksblat, Anne Kirstine Arveschoug, Jann Mortensen, Andreas Kjaer, Ulrich Knigge, Eva Tiensuu Janson & Seppo W. Langer. (2023) Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncologica 62:5, pages 431-437.
Read now
Eva Tiensuu Janson, Ulrich Knigge, Gitte Dam, Birgitte Federspiel, Henning Grønbaek, Peter Stålberg, Seppo W. Langer, Andreas Kjaer, Johanna Arola, Camilla Schalin-Jäntti, Anders Sundin, Staffan Welin, Espen Thiis-Evensen & Halfdan Sorbye. (2021) Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica 60:7, pages 931-941.
Read now

Articles from other publishers (9)

Rosaria M. Ruggeri, Irene Aini, Stefano Gay, Erika Maria Grossrubatscher, Camilla Mancini, Maria Grazia Tarsitano, Virginia Zamponi, Andrea M. Isidori, Annamaria Colao & Antongiulio Faggiano. (2023) Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders 25:2, pages 383-398.
Crossref
Giulia Santo, Gianpaolo Di Santo & Irene Virgolini. (2024) Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives. Seminars in Nuclear Medicine.
Crossref
Emilia Fortunati, Norma Bonazzi, Lucia Zanoni, Stefano Fanti & Valentina Ambrosini. (2023) Molecular imaging Theranostics of Neuroendocrine Tumors. Seminars in Nuclear Medicine 53:4, pages 539-554.
Crossref
. (2022) Lutetium-(177lu)-oxodotreotide/yttrium-90-dotatoc. Reactions Weekly 1936:1, pages 289-289.
Crossref
Kim R. Kennedy, John Harvey Turner, William B. G. MacDonald, Phillip G. Claringbold, Glenn Boardman & David T. Ransom. (2022) Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu‐octreotate peptide radionuclide therapy . Cancer 128:11, pages 2182-2192.
Crossref
Emilia Fortunati, Giulia Argalia, Lucia Zanoni, Stefano Fanti & Valentina Ambrosini. (2022) New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Current Treatment Options in Oncology 23:5, pages 703-720.
Crossref
Giulia Puliani, Alfonsina Chiefari, Marilda Mormando, Marta Bianchini, Rosa Lauretta & Marialuisa Appetecchia. (2022) New Insights in PRRT: Lessons From 2021. Frontiers in Endocrinology 13.
Crossref
Elettra Merola, Andrea Michielan, Umberto Rozzanigo, Marco Erini, Sandro Sferrazza, Stefano Marcucci, Chiara Sartori, Chiara Trentin, Giovanni de Pretis & Franca Chierichetti. (2022) Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World Journal of Gastrointestinal Surgery 14:2, pages 78-106.
Crossref
Peter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen & Anne Kirstine Arveschoug. (2021) Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Physics 8:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.